BiBBInstruments Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

BiBBInstruments şirketinin toplam hissedar öz sermayesi SEK34.5M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK37.2M ve SEK2.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 10.48m
Eşitlik	SEK 34.54m
Toplam yükümlülükler	SEK 2.66m
Toplam varlıklar	SEK 37.20m

Son finansal sağlık güncellemeleri

Is BiBBInstruments (NGM:BIBB) In A Good Position To Deliver On Growth Plans?

Dec 18

We're Keeping An Eye On BiBBInstruments' (NGM:BIBB) Cash Burn Rate

Dec 16

Recent updates

Is BiBBInstruments (NGM:BIBB) In A Good Position To Deliver On Growth Plans?

Dec 18

We're Keeping An Eye On BiBBInstruments' (NGM:BIBB) Cash Burn Rate

Dec 16

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BIBB 'nin kısa vadeli varlıkları ( SEK11.6M ) kısa vadeli yükümlülüklerini ( SEK2.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: BIBB un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BIBB borçsuzdur.

Borcun Azaltılması: BIBB son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BIBB şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: BIBB un, serbest nakit akışı her yıl % 1.6 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

BiBBInstruments Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is BiBBInstruments (NGM:BIBB) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On BiBBInstruments' (NGM:BIBB) Cash Burn Rate

Recent updates

BiBBInstruments AB to Report Q4, 2024 Results on Nov 08, 2024

BiBBInstruments AB Announces New Peer-Reviewed Clinical Case Series in the U.S. Shows 100% Diagnostic Accuracy with Endodrill Gi

BiBBInstruments AB Announces Successful Introduction of EndoDrill GI at University Hospital Center Sestre Milosrdnice in Zagreb, Croatia

BiBBInstruments AB to Report Q2, 2024 Results on Aug 21, 2024

BiBBInstruments AB Announces Successful Case Studies with EndoDrill GI Continue in Norway and Sweden

BiBBInstruments AB Announces Successful Clinical Pilot Study with EndoDrill GI Published in Peer Reviewed Scientific Journal

Bibbinstruments AB First Clinical Tissue Acquisition Procedures with Endodrill® Gi At Karolinska University Hospital in Stockholm Have Been Successfully Performed

BiBBInstruments AB to Report Q1, 2024 Results on May 03, 2024

Independent Director recently bought kr58k worth of stock

New major risk - Financial position

Chief Executive Officer recently bought kr101k worth of stock

Bibbinstruments AB Announces First US Clinical Cases Successfully Conducted with Endodrill GI

BiBBInstruments AB to Report Fiscal Year 2023 Results on Feb 09, 2024

BiBBInstruments AB to Report Nine Months, 2023 Results on Nov 10, 2023

Bibb Receives Approval of Two Patents in Europe for Endodrill

BiBBInstruments AB to Report Q2, 2023 Results on Aug 25, 2023

New major risk - Financial position

Chief Executive Officer recently bought kr102k worth of stock

New minor risk - Shareholder dilution

BiBBInstruments AB Reports Positive Results from Clinical Pilot Study with EndoDrill URO

Chief Executive Officer recently bought kr55k worth of stock

Chief Executive Officer recently bought kr60k worth of stock

BiBBInstruments AB to Report Fiscal Year 2022 Results on Feb 10, 2023

Less than half of directors are independent

BiBBInstruments AB to Report Q3, 2022 Results on Nov 11, 2022

BiBBInstruments AB to Report Q2, 2022 Results on Aug 26, 2022

Chairman of the Board recently bought kr64k worth of stock

BiBBInstruments AB, Annual General Meeting, Jun 14, 2022

BiBBInstruments Develops the CE-Marked Electromechanical Biopsy Instruments for Endoscopic Use

Less than half of directors are independent

BiBBInstruments AB to Report Q1, 2022 Results on May 06, 2022

Founder recently bought kr69k worth of stock

Is BiBBInstruments (NGM:BIBB) In A Good Position To Deliver On Growth Plans?

BiBBInsumentsts Cancer Study Comes to Early End After Convincing Data

Chairman of the Board recently bought kr73k worth of stock

BiBBinstruments AB Initiates Clinical Trial in Bladder Cancer

New 90-day high: kr9.50

We're Keeping An Eye On BiBBInstruments' (NGM:BIBB) Cash Burn Rate

New 90-day high: kr8.12

New 90-day high: kr6.14

BiBBInstruments AB to Report Q3, 2020 Results on Nov 13, 2020

New 90-day low: kr4.16

BiBBInstruments AB to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr5.20

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin